Kalorama Identifies Point-of-Care Testing Momentum and Strategic Blind Spots in Latest Diagnostic Trends Analysis
ARLINGTON, Va., June 23, 2025 /PRNewswire/ — With healthcare markets under pressure from newly implemented tariff policies, ongoing regulatory changes, and broader economic uncertainty, recent data from Kalorama Information reveals early indicators of where diagnostic demand may be headed next—and why industry leaders must closely monitor these shifts to adapt effectively.
Kalorama’s latest analysis, featured in the 2025 IVD Trends and Market Update, shows sustained growth in point-of-care (POC) testing, signaling more than just segment-level performance—it reflects deeper structural changes in how and where care is being delivered. The growing demand for decentralized testing suggests that providers are prioritizing faster, near-patient diagnostics in response to system-wide efficiency pressures, shifting care models, and increasing patient expectations.
These changes—compounded by newly enacted trade policies and regulatory fluctuations—are prompting diagnostic companies to reevaluate not just product development pipelines, but also commercial strategy, customer alignment, and market positioning.
The insights are featured in a free data highlight from the 2025 IVD Trends and Market Update, available now: Download the data highlight or explore the full report here: IVD Market Update 2025.
With tariffs in effect and regulatory frameworks still in flux, the clinical diagnostics market is in a period of continuous adjustment. As customer decision-making evolves alongside market conditions, it has become critical for manufacturers to not only interpret where the market is heading—but to reassess how these forces are influencing their customers’ needs and expectations.
Kalorama’s data illustrates that while trendlines can identify areas of growth—such as the momentum in POC testing—they do not on their own provide the full context needed to make targeted strategic decisions. These signals serve as a foundation but must be tracked and evaluated over time to inform business decisions about product direction, customer engagement, and market expansion.
Kalorama has observed that companies successfully navigating tariff-related disruption and broader economic shifts are those actively:
Realigning their commercial and product strategies with newly emerging or shifting provider priorities
Adjusting to changes in purchasing behavior driven by tariff implementation and regulatory change
Reevaluating product development focus and positioning based on up-to-date insight into segment viability and growth trajectories
“This is a time for proactive reassessment,” said Alisa Alvich, Marketing Director at Kalorama, part of Science and Medicine Group. “The diagnostic companies that are outperforming right now are the ones continuously tracking how market signals evolve—and using that intelligence to stay aligned with what their customers are actually experiencing and prioritizing.”
While the data highlight reflects current trends in diagnostic testing, Kalorama emphasizes that real strategic clarity comes from pairing syndicated market insights with tailored, business-specific intelligence that can guide decisions about pricing, product roadmaps, and market entry.
About Kalorama Information
Kalorama Information, part of Science and Medicine Group, has been a leading publisher of market research in medical markets, including the biotechnology, diagnostics, medical device, and pharmaceutical industries for more than 30 years. Our comprehensive, timely, quality research and innovative approach to analysis and presentation of market intelligence have made Kalorama Information a premier source of market information for top industry decision makers.
SOURCE Kalorama Information
